AroCell AB

Equities

AROC

SE0003883990

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 16:13:23 28/05/2024 BST			5-day change	1st Jan Change
0.405 ^SEK	+2.53%		+1.25%	-7.32%

05-03	AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Swedish Diagnostics Company AroCell Secures US Patent	MT

AroCell AB Appoints Michael Brobjer as New CEO

October 23, 2018 at 02:45 pm

Michael Brobjer has been appointed new CEO of AroCell AB and will join the company December 8, 2018. Michael Brobjer has also held the position as Marketing Manager and Responsible for Business Life Science within APL, which offers companies contract services in Life Science, and now last CEO of Karessa and Karessa Holding.

Latest news about AroCell AB

AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Swedish Diagnostics Company AroCell Secures US Patent	04-18	MT
AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
AroCell AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
AroCell Names CFO Goes on Parental Leave, Interim CFO Named	02-01	MT
AroCell AB Announces Chief Financial Officer Changes	02-01	CI
AroCell Wins Regulatory Nod for Typhoid Fever Rapid Test in Ethiopia	01-25	MT
AroCell AB Obtains Regulatory Approval for TUBEX® TF in Ethiopia	01-25	CI
AroCell AB Announces Results of Serum Tk1 Protein Levels Can Predict the Survival of Patients with Metastatic Prostate Cancer Patients	01-15	CI
AroCell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
AroCell AB Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer	18/09/23	CI
AroCell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/08/23	CI
AroCell AB Signs Additional Agreement with ZECEN Biotech Co., Ltd	17/07/23	CI
AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2023	03/05/23	CI
AroCell AB Announces TK1 together with PSA can predict more than 10 years differences in survival in men with prostate cancer	09/03/23	CI
Arocell AB Announces Improved Early Detection of Ovarian Cancer with Dual Biomarker Algorithm	06/03/23	CI
AroCell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23/02/23	CI
AroCell Signs Distribution Agreement in Ethiopia	01/02/23	CI
AroCell AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	27/10/22	CI
AroCell Signs Distribution Agreement with MM African Technology Covering Zambia and Malawi	19/10/22	CI
AroCell To Register TPS CLIA Tumor Marker In Chinese Market	06/09/22	MT
AroCell AB Expands Its Presence in the Chinese Market	06/09/22	CI
AroCell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	17/08/22	CI
AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument	13/06/22	CI
AroCell AB Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market	12/05/22	CI

Chart AroCell AB

Duration

Period

More charts

Company Profile

AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Sector

Biotechnology & Medical Research

Calendar

20/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for AroCell AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROCELL AB	-7.32%	8.85M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+37.09%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research